Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
Jul. 08, 2024 12:30 PM ET Eli Lilly and Company (LLY) Stock LLY:CA Stock MORF Stock ABBV ABBV:CA TAK TKPHF JNJ JNJ:CA PFE PFE:CA GILD SNY SNYNF GCVRZ Edmund Ingham Investing Group Leader Follow Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectable entyvio. Study data for MORF-057 has been somewhat mixed, and Wall Street seemed to have lost faith - Lilly, however, is paying an 85% premium to the traded price for Morphic. Thanks to the $50bn per annum revenue promise of its wonder-drug tirzepatide and the double-digit billion potential of Alzheimer's drug Kisunla, Lilly can afford to make more speculative M&A deals than rival pharmas. The Morphic deal strikes me as a calculated gamble that could be unsuccessful or deliver a $5bn per annum drug. In the latter
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list [Yahoo! Finance Canada]Yahoo! Finance Canada
- What end of Eli Lilly's weight-loss drug shortage means for the competition [Yahoo! Finance]Yahoo! Finance
- England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access [Yahoo! Finance]Yahoo! Finance
- NHS proposes phased launch for Eli Lilly's Mounjaro [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website